Post-market studies on generic drugs track real-world safety after FDA approval. With no new clinical trials, surveillance through MedWatch, Sentinel, and manufacturer reporting catches hidden risks like inconsistent dissolution, patch failures, and rare side effects missed in small trials.
Jan, 4 2026
